The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2

The SARS-CoV-2 variant is rapidly spreading across the world and causes to resurge infections. We previously reported that CT-P59 presented its in vivo potency against Beta variants, despite its reduced activity in cell experiments. Yet, it remains uncertain to exert the antiviral effect of CT-P59 o...

Descripción completa

Detalles Bibliográficos
Autores principales: Ryu, Dong-Kyun, Kang, Bobin, Noh, Hanmi, Woo, Sun-Je, Lee, Min-Ho, Nuijten, Patricia M., Kim, Jong-In, Seo, Ji-Min, Kim, Cheolmin, Kim, Minsoo, Yang, Eunji, Lim, Gippeum, Kim, Seong-Gyu, Eo, Su-Kyeong, Choi, Jung-ah, Song, Manki, Oh, Sang-Seok, Chung, Hyo-Young, Tijsma, Aloys SL., van Baalen, Carel A., Kwon, Ki-Sung, Lee, Soo-Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436435/
https://www.ncbi.nlm.nih.gov/pubmed/34547629
http://dx.doi.org/10.1016/j.bbrc.2021.09.023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436435/
https://www.ncbi.nlm.nih.gov/pubmed/34547629
http://dx.doi.org/10.1016/j.bbrc.2021.09.023

Ejemplares similares